...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of clinical oncology >Knowledge base toward understanding actionable alterations and realizing precision oncology
【24h】

Knowledge base toward understanding actionable alterations and realizing precision oncology

机译：了解可行的改变和实现精密肿瘤学的知识基础

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In Japan, the National Cancer Center and university hospitals have initiated next-generation sequencing-based in vitro diagnostic testing for cancer patients as a method of clinical sequencing. Based on the molecular alterations detected, physicians can provide approved targeted therapy and access to investigational drugs for cancer patients. However, interpretation of the clinical significance of genomic alterations remains the most severe bottleneck of precision medicine in cancer. Although many research institutes in the United States are developing knowledge bases for interpretation of the tumor alterations and clinical decisions, these knowledge bases are unsuited as sources of reference in Japan due to differences in the information on approved drugs and implementation of clinical trials. In this review, we introduce knowledge bases for clinical decision-making based on genomic events in cancer, and discuss the resources of additional information necessary for implementing precision medicine in Japan.
机译：在日本，国家癌症中心和大学医院已经开始为癌症患者的下一代序列的体外诊断检测作为一种临床测序方法。基于检测到的分子改变，医生可以提供批准的靶向治疗和获取癌症患者的调查药物。然而，对基因组改变的临床意义的解释仍然是癌症精密药物最严重的瓶颈。虽然美国的许多研究机构正在制定知识库，以便解释肿瘤改变和临床决策，但这些知识库是由于批准药物信息和临床试验的实施信息的差异而导致日本的参考来源。在本文中，我们向基于癌症的基因组事件介绍了知识库，以促进基因组事件，并讨论在日本实施精密药物所需的附加信息资源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号